Antidiabetic effects associated with salicylates have been known for years, although the underlying mechanisms were not understood. We have been reinvestigating these effects in the light of recent discoveries in the areas of signal transduction and insulin resistance. Our findings showed that signaling pathways leading to IkB kinase b (IKKb) and NF-kB are activated in insulinresponsive tissues of obese and high-fat-fed animals. Since activation correlates with the development of insulin resistance, we asked whether signaling through this might be involved in the pathogenesis of insulin resistance. Heterozygous gene deletion (Ikkb þ /À) or salicylates, working as IKKb inhibitors, improved insulin sensitivity in insulin-resistant rodent models. Furthermore, high doses of salicylates (aspirin or salicylate) improved insulin sensitivity in patients with type II diabetes. Our studies implicate an inflammatory process in the pathogenesis of insulin resistance in obesity and type II diabetes mellitus and identify the IKKb/ NF-kB pathway as a molecular mediator of insulin resistance and pharmacological target for insulin sensitization.
Introduction

Historical use of salicylates in diabetes
We have used the glucose-lowering effects of salicylates to investigate potential mechanisms of hyperglycemia in type II diabetes. Early reports from the 19th and turn of the 20th centuries described the experimental use of high doses (5-7.5 g/day) of sodium salicylate to treat diabetes mellitus. 1, 2 Marked reductions in glycosuria were accompanied by an improved sense of well-being in selected patients with 'the milder form of the disease'. Presumably this would now be categorized as type II diabetes. The inability to distinguish etiologies at the time undoubtedly led to attempts to treat patients with type I diabetes as well, although this would likely have had adverse consequences. Interest was renewed during the 1950s following a report by Reid and colleagues 3 about a young insulin-treated diabetic patient who was taking over 6 g/day of aspirin for acute rheumatic fever. Blood glucose concentrations were normalized, even during glucose tolerance testing and despite his having discontinued exogenous insulin. Sufficiently intrigued by these findings, seven additional diabetic patients treated with high-dose aspirin confirmed its hypoglycemic effects. 3 Additional contemporaneous studies similarly concluded that in diabetic patients 1-to 3-week trials of high-dose aspirin were able to lowerFand often normalizeFblood and urine glucose levels. 4, 5 As the importance of insulin secretion in the development of diabetes was appreciated at the time, investigations during ensuing years focused primarily on possible roles of salicylates in promoting insulin secretion. However, the results of numerous in vitro and in vivo studies, reviewed by Baron, 6 were inconclusive, in part because dosages and acute and chronic effects were poorly distinguished. Since insulin action at the time was a 'black box', notions about what might form the molecular bases of insulin resistance were understandably primitive. To our knowledge insulin sensitization had not previously been considered seriously as a potential mechanism for the antidiabetic effects of high-dose aspirin and salicylate.
Insulin action and potential molecular targets of highdose salicylates The potential relationships between inflammation and insulin resistance have been promoted by Hotamisligil and Spiegelman. [7] [8] [9] Their earlier studies focused on production of tumor necrosis factor-a (TNF-a) by adipose tissue and the ability of TNF-a to suppress signaling mediated by the insulin receptor (IR) and its substrates (IRSs). While the degree to which TNF-a itself mediates insulin resistance in humans is controversial, their findings clearly defined the potential for insulin resistance to be caused by cross-talk between inflammatory (TNF-a) and metabolic (IR/IRS) signaling cascades. On this setting a final major clue pointed to the IKKb/NFkB inflammatory pathway as a potential mediator of insulin resistance. The efficacy of salicylates, including aspirin, as anti-inflammatory drugs had been widely attributed to their inhibitory effects on prostaglandin production. The cyclooxygenase enzymes, aspirin's direct targets at the typical dose of 650 mg, catalyze the conversion of arachidonic acid to prostaglandin H 2 . Prostaglandin H 2 is a biosynthetic precursor of additional prostaglandins that mediate inflammatory responses. Two genes encode two forms of cyclooxygenase: COX1 is constitutively expressed, whereas COX2 is considered to be inducible. Upon binding, aspirin's acetyl group is transferred to serine residues within the enzymes' active sites, leading to irreversible inactivation. Even at low daily doses of 80-100 mg, aspirin has potent antithrombotic effects through its inhibition of COX1 in platelets. Since platelets lack the capacity to synthesize new proteins, a single dose effectively wipes out COX1 activity for the lifetime of the platelet.
Salicylates that lack an acetyl group (eg sodium salicylate and the esterified dimer, salsalate) are much weaker inhibitors of COX1 and COX2 due to their inability to transacetylate and irreversibly modify the enzymes. Yet comparable dosages of salicylic acid and aspirin effectively treat certain chronic inflammatory conditions (eg rheumatoid arthritis), suggesting the existence of another molecular target distinct from the cyclooxygenases. Studies reported by Kopp and Ghosh 10 indicated that at high concentrations, salicylates inhibited the activation of NF-kB, a transcription factor that is activated by inflammatory stimuli including TNF-a. NF-kB drives the production of numerous proinflammatory cytokines, including interleukin (IL)-1b, TNF-a, IL-6 and interferon b. NF-kB is inhibited by IkB under basal conditions, and remains in the cytoplasm. Upon activation of proinflammatory inputs, the kinase complex referred to as IKK is activated and catalyzes the phosphorylation of IkB. This leads to IkB degradation, which liberates NF-kB to translocate into the cell nucleus and stimulate the transcription of inflammatory mediators. Findings by Gaynor and coworkers 11 indicated that IKKb, one of the kinases in the IKK complex, is a direct molecular target of the salicylates. The stage was thus set to ask whether the glucose-lowering effects of high-dose salicylates were mediated by inhibiting the IKKb/NF-kB axis.
IKKb as a mediator of insulin resistance and target for its reversal
Numerous serine-and threonine-directed kinases have been shown to induce 'insulin resistance' like states, at least in vitro. This appears to be due to Ser/Thr phosphorylation of IR or IRSs, which reduces normal signaling through tyrosine phosphorylation. Since inflammation activates cascades of Ser/Thr kinases and causes insulin resistance, we wondered whether an inflammation-activated kinase mediated insulin resistance. Based on the realization that salicylates not only inhibited an inflammatory kinase (IKKb) but also reversed hyperglycemia in diabetic patients, our studies focused squarely on IKKb as a potential mediator of insulin resistance. 12 We looked initially at the effects of high-dose aspirin and sodium salicylate in obese rodent models of severe insulin resistance, including Zucker fatty rats and ob/ob mice. 12 Subcutaneous delivery of the drugs at dosages of 120 mg/kg/ day for 3-4 weeks was accompanied by dramatic reductions in insulin resistance, as signaled by improved sensitivity to exogenous insulin in insulin tolerance tests and reductions in blood glucose and insulin concentrations during glucose tolerance testing. Significant reductions were seen as well in triglyceride and free fatty acid levels. Hepatotoxicity, which has been reported with aspirin and salicylate overdose, was not observed during these trials, as judged by normal liver transaminase levels throughout. Harvested skeletal muscle and liver tissues revealed reversals of blunted insulin signaling in the treated animals compared to untreated controls.
The ability of salicylates to reverse 'insulin resistance' was further examined using TNF-a-and calyculin A-treated 3T3-L1 (fat) and Fao (liver) cells. Consistent with IKKb being the target as opposed to the cyclooxygenases, other NSAIDs that selectively target COX1 and/or COX2 were unable to reverse diminished signaling through IR and the IRSs. Expression of IKKb or an activator of it inhibited IR activation, whereas expression of a dominant inhibitory form of IKKb blocked TNF-a-induced 'insulin resistance', consistent with the possibilities that IKKb activation causes insulin resistance and IKKb inhibition reverses it. It is important to stress the serious limitations of using cultured cells to study insulin resistance, an in vivo disorder that affects multiple tissues.
Additional studies asked whether reductions in tissue levels of IKKb influenced in vivo insulin sensitivity. Whereas homozygous deletion of Ikkb is embryonic lethal due to massive apoptosis in the liver, 13, 14 heterozygous Ikkb þ /À mice had been reported to be normal. Fasting and postglucose challenge blood glucose and insulin levels were consistently lower in the Ikkb þ /À mice compared to wildtype littermates, whether they were fed regular chow or a high-fat diet. 12 Additional crossings showed that the Ikkb þ /À genotype on an ob/ob background had consistently lower blood glucose values than Ikkb þ / þ ob/ob littermates.
Therefore, a 50% reduction in gene dose, and the associated 50% reduction in protein concentrations, brought about substantial reductions in blood glucose levels and improvements in insulin sensitivity. Positive results were seen with chow-and high-fat-fed mice and genetically obese mice to validate IKKb as useful new drug target.
Acute elevations in plasma free fatty acids during intralipid infusion lead to insulin resistance in muscle and liver. 15, 16 PKC isoforms activated in the muscle of rodents and humans by acute elevations in circulating free fatty acids may in turn activate the IKKb/NF-kB axis. 17, 18 Consistent with this hypothesis and with a role for the IKKb/NF-kB axis in the development of insulin resistance in the lipid infusion model, salicylate and heterozygous deletion of Ikkb both protected against the development of insulin resistance during fatty acid infusion in rats. 19 The effects of high-dose aspirin (B7 g/day) on insulin resistance, recently re-evaluated in type II diabetic patients, revealed an B20% reduction in the basal rates of hepatic glucose production and an B20% improvement in insulinstimulated peripheral glucose disposal. 20 Treatment was associated with an B25% reduction in fasting glucose levels, an B15% reduction in total cholesterol and C-reactive protein, and B50% reductions in fasting triglyceride and free fatty acid concentrations, despite there being no change in body weight. During mixed meal tolerance testing, areas under the curves decreased B20% for plasma glucose and B50% for free fatty acids. Although the results were confounded by B30% decrease in insulin clearance during the hyperinsulinemic-euglycemic clamps, which led to increased insulin levels during the treatment phase of the protocol, when insulin levels were matched by adjusting the insulin infusion rates, significant improvements of insulin resistance remained. We concluded from these data that IKKb represents a valuable new target for developing treatments for patients with type II diabetes.
Future directions
As is often the case with new discoveries, many more questions need to be answered. Some of those currently being addressed are outlined below, although this list is surely incomplete.
Can salicylates be used to treat patients with type II diabetes?
The high doses of aspirin necessary to substantially impact insulin resistance have serious side effects. The potential for causing serious gastrointestinal bleeding precludes its use as anything but an investigational agent, and it must be carefully monitored in this setting. Salicylate, on the other hand, is much less of a problem. Since it does not acetylate the cyclooxygenases, it does not inhibit platelet function. Salicylate itself is irritating to the stomach lining, but the head-to-tail dimer of salicylate (salsalate or Disalcid) is insoluble at the acid pH of the stomach. It is hydrolyzed at neutral pH in the small bowel to form salicylate, and efficiently absorbed. Bleeding times are normal in patients taking up to 3 g/day of salsalate. Preliminary results from our lab suggest that salsalate administration (4.5 g/day) is as effective as high-dose aspirin in the short term (Waleed Aldhahi, Allison Goldfine and Steve Shoelson, unpublished result). Additional studies should determine whether efficacy remains using lower doses, such as those approved by the FDA for treating arthritis (3 g/day), and longer durations.
Do other inhibitors of IKKb improve insulin resistance?
The short answer is yes, it appears that they do, although results must be treated as preliminary since they have not yet been peer-reviewed or published. We have looked in detail at two natural products with anti-inflammatory properties whose mechanisms of action are reportedly through IKKb inhibition. Both are orally active insulin sensitizers, as assessed in genetically obese and high-fat fed rodent models of insulin resistance, with similar effects to those seen with salicylate but at lower dosages.
Which tissues are responsible for the insulin sensitizing effects of IKKb inhibition? Although NF-kB was originally identified in lymphocytes, its role as a central mediator of immune and inflammatory responses has expanded with time. It is now known to be widely expressed in many tissues, although functions outside of cells involved directly in immune and inflammatory responses are only beginning to be understood. Wherever NF-kB is expressed, inhibitory IkB and the IKK kinase complexes appear to be expressed as well, consistent with their critical roles in regulating NF-kB function. Since insulin resistance is usually considered to have primary pathological consequences in such insulin-responsive tissues as liver, muscle and fat, these are obvious places to begin the search. Insulin normally suppresses glucose production in liver and promotes glycogen storage, but fails to adequately do so when there is insulin resistance, which contributes to hyperglycemia in type II diabetes. The blunting of insulinstimulated glucose uptake into fat and muscle, which results from insulin resistance in these tissues, similarly contributes to hyperglycemia in type II diabetes. Series of new genetic models that we have created should help to define which tissues are involved in initiating inflammation-mediated insulin resistance. Coupled with the profiling of gene expression in these tissues, we hope to get handles on which pathways initiate the inflammatory cycle that appears to be at the root of insulin resistance.
